Basal cell carcinoma
☆ AI Dermatology — Free Service
Katika matokeo ya 2022 ya Stiftung Warentest kutoka Ujerumani, kuridhika kwa watumiaji na ModelDerm kulikuwa chini kidogo kuliko na mashauriano ya matibabu ya simu yanayolipishwa.
Katika matokeo ya 2022 ya Stiftung Warentest kutoka Ujerumani, kuridhika kwa watumiaji na ModelDerm kulikuwa chini kidogo kuliko na mashauriano ya matibabu ya simu yanayolipishwa.
Vidonda vilivyokuwa na uvimbe vinavyoathiri ngozi ya pua kwa mtu mzee mara nyingi hutambuliwa kama Basal cell carcinoma. Pua ni mahali pa kawaida pa kutokea kwa aina hii ya saratani ya ngozi.
Basal cell carcinoma inaweza kudhaniwa kuwa kiwondo (wart).
relevance score : -100.0%
ReferencesBasal cell carcinoma (BCC) ndio aina ya saratani ya ngozi inayojulikana zaidi. Mfiduo wa jua ndio sababu kuu. Takriban kesi zote vya BCC vinaonyesha ishara ya Hedgehog iliyokithiri katika uchanganuzi wa molekuli. Matibabu tofauti yanapatikana na kuchaguliwa kulingana na hatari ya kujirudia, umuhimu wa uhifadhi wa tishu, upendeleo wa mgonjwa, na kiwango cha ugonjwa.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinomas ndio aina ya saratani ya ngozi inayojulikana zaidi kwa watu wazima wenye ngozi nyeupe wenye umri wa miaka 50 na kuendelea. Idadi yao inaongezeka ulimwenguni pote, haswa kutokana na kufichuliwa na jua. Hali fulani za kijeni zinaweza kuwafanya watu wawe na uwezekano wa kupata saratani hizi katika umri mdogo. Basal cell carcinomas hutofautiana katika ukali, kuanzia vidonda vya juu vinavyoweza kutibika kwa urahisi hadi vile vikubwa zaidi vinavyohitaji majadiliano katika timu maalum za matibabu. Ubashiri hutegemea uwezekano wa saratani kurudi au uwezo wake wa kuharibu tishu zilizo karibu. Upasuaji ndio matibabu ya kawaida kwa kesi nyingi, kuhakikisha kuondolewa kwa usahihi na uwezekano mdogo wa kurudia. Mbinu zisizo za upasuaji zinaweza kutibiwa kwa ufanisi vidonda vya juu.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Tiba kuu ya BCC ni upasuaji. Kwa hatari kubwa au inayorudiwa ya BCC, hasa katika maeneo muhimu, upasuaji unaodhibitiwa kwa micrographically unapendekezwa. Wagonjwa walio na hatari ndogo ya BCC ya uso wanaweza kuzingatia matibabu ya topiki au mbinu za uharibifu. Tiba ya Photodynamic hufanya kazi vizuri kwa BCC za uso na nodula zenye hatari ndogo. Kwa BCC ya hali ya juu au metastatic, vizuizi vya Hedgehog (vismodegib, sonidegib) vinapendekezwa. Ikiwa kuna maendeleo ya ugonjwa au kutovumilia kwa vizuizi vya Hedgehog, tiba ya kinga na anti-PD1 antibody (cemiplimab) inaweza kuzingatiwa. Tiba ya mionzi ni chaguo nzuri kwa wagonjwa ambao hawawezi kufanyiwa upasuaji, hasa wagonjwa wazee. Electrochemotherapy inaweza kuzingatiwa ikiwa upasuaji au radiotherapy sio chaguo.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Mambo ya hatari ni pamoja na kukabiliwa na mwanga wa ultraviolet, tiba ya mionzi, mfiduo wa muda mrefu wa arseniki na utendaji duni wa mfumo wa kinga (k.m. upandikizaji wa chombo). Mfiduo wa mwanga wa UV wakati wa utotoni ni hatari sana.
Baada ya uchunguzi wa biopsy, matibabu ni kawaida kwa kuondolewa kwa upasuaji. Hii inaweza kuwa kwa kukatwa rahisi ikiwa saratani ni ndogo; Ikiwa saratani si ndogo, upasuaji wa Mohs unapendekezwa kwa ujumla.
Basal cell carcinoma inachukua angalau 32% ya saratani zote ulimwenguni. Kati ya saratani za ngozi isipokuwa melanoma, karibu 80% ni saratani za seli za basal. Nchini Marekani, karibu 35% ya wanaume weupe na 25% ya wanawake weupe huathiriwa na basal cell carcinoma wakati fulani katika maisha yao.
○ Uchunguzi na Tiba
#Dermoscopy
#Skin biopsy
#Mohs surgery